Firms sign first Israeli-Emirati biomed deal

Israeli biotech firm MediWound has signed a commercial agreement with Dubai-based Ghassan Aboud Group (GAG) to market their NexoBrid product, it announced Tuesday. This first Israeli-Emirati bio-med agreement follows a month of digital webinars in October arranged by Abu Dhabi-based Cosmopole and Tel Aviv-based Kamir Strategy, in which the company participated. NexoBrid removes eschar (dead skin tissue) from burn victims and has FDA approval. GAG, which is owned by Syrian businessman Ghassan Aboud, gained exclusive rights to market and distribute the product in the UAE once it has regulatory approval, which is expected to happen next year, Globes reported. “We are proud to enter into our first partnership in the Middle East,” MediWound CEO Sharon Malka said. “Together with GAG, we will be able to open up new opportunities for NexoBrid across the region.” Aboud said his 26-year-old firm has one goal: “Always to pioneer, excel and make an impact.” He said he was certain the market reach and distribution network his company has, coupled with the innovative drug, will “improve the standard of care of burn patients” everywhere. In 2018, Forbes Middle East said Aboud was one of the 50 most powerful expats living in the UAE. His business empire includes Live Point Art production, which produces news and other programs for the Arab-speaking world; the satellite channel Orient Media; and extensive holdings in Australia in the hotel and farming sectors. Yavne-based MediWound's solution achieves results in roughly four hours without damaging surrounding healthy tissues, the Post reported two years ago.

Firms sign first Israeli-Emirati biomed deal

MediWound signs NexoBrid agreement with Ghassan Aboud Group

New Israeli app tracks disaster victims in real time

US inflation spikes due to Iran conflict, rising oil prices

Firms sign first Israeli-Emirati biomed deal

MediWound signs NexoBrid agreement with Ghassan Aboud Group

See more on